Table 3 (A) transplantation outcomes, (B) transplantation outcomes: sAML per antecedent hematological disorder versus de novo AML

de novo

19.5% [17.2–21.8]

21.1% [18.9–23.4]

59.5% [56.6–62.2]

65.4% [62.5–68]

49.9% [47–52.7]

sAML

21.3% [15.6–27.5]

20.8% [15.4–26.7]

58% [50.5–64.7]

65.7% [58.3–72.1]

47% [39.5–54.1]

P value

0.39

0.72

0.28

0.35

0.5

de novo

27.2% [24.9–29.6]

9.2% [7.7–10.8]

32.2% [29.5–34.9]

11.9% [10.1–13.9]

secAML

29.1% [23.1–35.3]

6.6% [3.8–10.4]

33.3% [26.5–40.3]

11.3% [7.1–16.6]

P value

0.55

0.23

1

0.48

de novo

19.5% [17.2–21.8]

21.1% [18.9–23.4]

59.5% [56.6–62.2]

65.4% [62.5–68]

49.9% [47–52.7]

MDS/MPN/BMFS

21.6% [14.6–29.6]

17.3% [11.3–24.2]

61.1% [51.7–69.2]

70.6% [61.5–77.8]

46.9% [37.4–55.8]

OMHD/ST

20.7% [11.9–31.2]

27.1% [17.2–38.1]

52.2% [39.6–63.4]

57.1% [44.2–68.1]

46.7% [34.3–58.1]

P value

0.68

0.58

0.3

0.22

0.79

de novo

27.2% [24.9–29.6]

9.2% [7.7–10.8]

32.2% [29.5–34.9]

11.9% [10.1–13.9]

MDS/MPN/BMFS

30.9% [23.4–38.7]

6.5% [3.2–11.4]

38.2% [29.2–47.1]

13.7% [7.9–21.1]

OMHD/ST

25.7% [16.3–36.1]

6.8% [2.5–14]

24.4% [14.7–35.4]

7.4% [2.7–15.3]

P value

0.59

0.49

0.19

0.36